Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Technology May Prove Critical in New Cancer Drug Development

November 19, 2019 13:18:17
  • Predictive Oncology subsidiary TumorGenesis developing new PDx models needed to understand the complexities of cancer
  • Tremendous unmet need for patient-derived tumors (PDx) for new drug development – current mouse models unreliable
  • TumorGenesis unique in the industry; its ovarian-cancer cells haven’t been widely available like most other PDx samples
  • Multi-billion-dollar market opportunity

As the precision-medicine industry continues to integrate technology to improve the efficiency and efficacy of its strategies, clinicians are realizing the need for actual patient samples to determine the best methods to defeat cancer. Researchers are now turning to patient-derived tumors (PDx) to better understand the complexities and vagaries of the disease which has become the new focus in cancer research. Predictive Oncology Inc. (NASDAQ: POAI) is executing on its mission to deliver cutting-edge services for the oncology research and profiling market. The company’s subsidiary, TumorGenesis, was formed in 2018 with a mission to create reliable, reproducible and translatable cancer cell capture, culture and screening using lab-ready to use technologies.

TumorGenesis will build kits used in cancer research laboratories around the world. Kits, media and cells are valued today at $2.8 billion growing at CAGR 12.9% to $6.8 billion by 2025.Predictive Oncology believes TumorGenesis’ novel PDx platform will provide pharmaceutical and biotech companies the tools needed to…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.